High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma
18 Years
61 Years
Both
Lymphoma, Non-Hodgkin, Blood and Marrow Transplant (BMT), Lymphomas: Non-Hodgkin
Trial Information
High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma
To determine safety and toxicity of a regimen of high dose chemotherapy with allogeneic
peripheral blood progenitor cell transplantation; determine the efficacy of the procedure by
following clinical outcomes and quality of life measures; and evaluate graft versus host
disease incidence and severity with regimen.
Inclusion Criteria:
Morphologically confirmed relapsed non-Hodgkin's lymphomaAge: >18 and <61 years of age
Signed informed consent
Exclusion Criteria:Hepatic dysfunction defined by serum transaminases >2.5X normal values
Serum creatinine of > 2 mg/dl or creatinine clearance < 60 ml/min
Diseases other than non-Hodgkin's lymphoma
Prior bone marrow transplant procedure
Severe psychological or medical illness
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Safety
Outcome Time Frame:
unknown
Safety Issue:
Yes
Principal Investigator
Wen-Kai Weng
Investigator Role:
Principal Investigator
Investigator Affiliation:
Stanford University
Authority:
USA:IRB
Study ID:
BMT4L
NCT ID:
NCT00186394
Start Date:
April 2000
Completion Date:
December 2006
Related Keywords:
- Lymphoma, Non-Hodgkin
- Blood and Marrow Transplant (BMT)
- Lymphomas: Non-Hodgkin
- Lymphoma
- Lymphoma, Non-Hodgkin
Name | Location |
|---|---|
| Stanford University School of Medicine | Stanford, California 94305-5317 |
